QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

LXRX

QT55Lexicon Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
2.01
-0.03-1.47%
OverviewShort InterestFilings
LXRXQT55Lexicon Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
2.01-1.47%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.07
Insider Own-
Shs Outstand444.20M
Perf Week6.35%
Market Cap906.16MForward P/E-EPS next Y-0.21Insider Trans6.24%Shs Float-Perf Month-5.63%
Enterprise Value925.78MPEG-EPS next Q-Inst Own-Short Float-Perf Quarter24.07%
Income-28997115.00P/S13.01EPS this Y-126.66%Inst Trans-Short Ratio-Perf Half Y67.50%
Sales69.64MP/B4.03EPS next Y-30.01%ROA-9.71%Short Interest-Perf YTD74.78%
Book/sh0.46P/C-EPS next 5Y-ROE-18.64%52W High2.53 -20.55%Perf Year178.93%
Cash/sh0.39P/FCF-EPS past 3/5Y-ROIC-9.30%52W Low0.70 185.92%Perf 3Y-
Dividend Est.-EV/EBITDA-53.08Sales past 3/5Y- 15.81%Gross Margin99.07%Volatility4.27% 4.15%Perf 5Y-
Dividend TTM-EV/Sales13.29EPS Y/Y TTM-Oper. Margin-34.79%ATR (14)0.13Perf 10Y-
Dividend Ex-Date-Quick Ratio18.77Sales Y/Y TTM122.58%Profit Margin-37.46%RSI (14)53.01Recom2.79
Dividend Gr. 3/5Y-Current Ratio18.79EPS Q/Q-SMA200.40%Beta1.76Target Price6.00
Payout0.00%Debt/Eq0.28Sales Q/Q2000.00%SMA504.39%Rel Volume1.59Prev Close2.04
Employees103LT Debt/Eq0.52Earnings-SMA20031.95%Avg Volume2.47MPrice2.01
IPO DateApr 07, 2000Option/ShortNo / YesEPS/Sales Surpr.-Net Debt/EBITDA-1.12Volume3,924,081Change-1.47%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-12-26ReiteratedH.C. WainwrightBuy$6.00
Mar-04-25DowngradeLeerink PartnersOutperform → Market Perform
Oct-18-24ReiteratedLeerink Partners$6.00
Jan-29-21UpgradeJP MorganUnderweight → Neutral
Jan-29-21DowngradeWedbushOutperform → Neutral
Dec-08-20UpgradeCitigroupNeutral → Buy
Nov-18-20UpgradeGabelli & Co.Hold → Buy
Dec-11-19DowngradeGabelli & Co.Buy → Hold
Nov-08-19DowngradeCitigroupBuy → Neutral
Sep-11-19UpgradeGabelli & Co.Hold → Buy
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue695031
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A001
Gross Profit695030
Selling, General and Administrative Excl. Other3537132
Research and Development596184
Other Operating Expense-1012
Operating Income-24-49-197
Interest Expense8816
Unusual Expense
———
Non-Operating Income (Expense)-7-7-12
Net Income Before Taxes-27-50-200
Income Taxes000
Consolidated Net Income-27-50-200
Net Income From Continuing Operations-27-50-200
Net Income-27-50-200
EPS (Recurring)-0.07-0.14-0.63
EPS (Basic, Before Extraordinaries)-0.07-0.14-0.63
EPS (Diluted)-0.07-0.14-0.63
EBITDA-16-41-184
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio11.658.35—
Gross Margin100.00100.0096.77
Operating Margin-34.78-98.00-635.48
Net Margin-39.13-100.00-645.16
Shares Outstanding400363320
Market Capitalization804417—
Operating Lease Expense
———
Insider Trading Volume
$2.16$1.96$1.77$1.57$1.38● Close Price0.00M0.68M1.36M2.04M2.72MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Swain Judith LDirectorJun 03 '26Option Exercise0.00178,6240174,486Jun 04 12:00 AM
Sullivan Diane E.DirectorJun 03 '26Option Exercise0.00178,6240126,122Jun 04 12:00 AM
SOBECKI CHRISTOPHER JDirectorJun 03 '26Option Exercise0.00178,6240293,177Jun 04 12:00 AM
Cheung IvanDirectorJun 03 '26Option Exercise0.00178,624089,312Jun 04 12:00 AM
BARKER SAM LDirectorJun 03 '26Option Exercise0.00178,6240213,771Jun 04 12:00 AM
Amouyal PhilippeDirectorJun 03 '26Option Exercise0.00178,6240374,486Jun 04 12:00 AM
DEBBANE RAYMONDDirectorJun 03 '26Option Exercise0.00178,62401,995,498Jun 04 12:00 AM
Artal Participations S.a r.l.director, 10 percent owner:Apr 30 '26Option Exercise0.0020,830,1700175,156,062May 08 12:00 AM
McDermott WendySVP, Human ResourcesFeb 28 '26Option Exercise0.00448,8120346,052Mar 03 12:00 AM
Martens Rachel YapSVP, Partnerships & Corp StratFeb 28 '26Option Exercise0.00134,1800134,180Mar 03 12:00 AM
Granowitz Craig BSVP, Chief Medical OfficerFeb 28 '26Option Exercise0.00624,5520432,528Mar 03 12:00 AM
Gopinathan SumaSVP, DiscoveryFeb 28 '26Option Exercise0.00199,9000174,470Mar 03 12:00 AM
DeFrancesco LisaSVP, IR and Corp CommFeb 28 '26Option Exercise0.00305,7280256,380Mar 03 12:00 AM
Crum Brian TSVP, General Counsel & Secr.Feb 28 '26Option Exercise0.00546,0120533,821Mar 03 12:00 AM
Coiante Scott MSVP, Chief Financial OfficerFeb 28 '26Option Exercise0.00320,4740320,473Mar 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR